Education
About Us
Working with TipRanks
Follow Us
Kodiak Sciences Inc (KOD)
NASDAQ:KOD
KOD Stock Chart & Stats
$22.38
-$0.42(-4.39%)
At close: 4:00 PM EST
$22.38
-$0.42(-4.39%)
Day’s Range― - ―
52-Week Range$1.92 - $31.18
Previous CloseN/A
Volume87.32K
Average Volume (3M)761.59K
Market Cap
$1.37B
Enterprise Value$1.17B
Total Cash (Recent Filing)$72.04M
Total Debt (Recent Filing)$62.20M
Price to Earnings (P/E)―
Beta2.81
Next Earnings
Mar 26, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding61,048,428
10 Day Avg. Volume687,341
30 Day Avg. Volume761,588
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.48
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-44.35
Enterprise Value/Ebitda-6.16
Forecast
1Y Price Target
$31.80Price Target Upside42.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ABC Reformulation BenefitsAnalyst notes the antibody biopolymer conjugate reformulation is designed to combine immediate antibody activity with extended durability, which could reduce injection frequency and improve patient acceptance compared with current anti‑VEGF options.
Analyst Conviction And OutlookAnalyst upgraded to a Buy and increased conviction ahead of pivotal readouts, signaling that successful Phase 3 results could materially validate the platform and support stock upside.
KSI-101 Early EfficacyAnalyst highlights Phase 1b APEX data showing sustained retinal drying and vision improvements for KSI-101, suggesting the dual IL‑6/VEGF mechanism could deliver best‑in‑class efficacy potential.
Bears Say
Historical Trial Failures And Safety UncertaintyAnalyst flags prior trial failures and an unexpected increase in cataract events as key uncertainties, leaving open questions about whether the reformulated approach will deliver improved safety and efficacy in larger trials.
Limited Cash RunwayAnalyst warns the company has a limited cash runway of under one year, heightening the risk of dilutive financing or operational constraints if pivotal programs face delays.
Market Skepticism And Short InterestAnalyst notes elevated short interest and program risk concerns, which could amplify share volatility around clinical readouts and regulatory developments.
Kodiak Sciences News
KOD FAQ
What was Kodiak Sciences Inc’s price range in the past 12 months?
Kodiak Sciences Inc lowest stock price was $1.92 and its highest was $31.18 in the past 12 months.
What is Kodiak Sciences Inc’s market cap?
Kodiak Sciences Inc’s market cap is $1.37B.
When is Kodiak Sciences Inc’s upcoming earnings report date?
Kodiak Sciences Inc’s upcoming earnings report date is Mar 26, 2026 which is in 49 days.
How were Kodiak Sciences Inc’s earnings last quarter?
Kodiak Sciences Inc released its earnings results on Nov 13, 2025. The company reported -$1.16 earnings per share for the quarter, missing the consensus estimate of -$1.037 by -$0.123.
Is Kodiak Sciences Inc overvalued?
According to Wall Street analysts Kodiak Sciences Inc’s price is currently Undervalued.
Does Kodiak Sciences Inc pay dividends?
Kodiak Sciences Inc does not currently pay dividends.
What is Kodiak Sciences Inc’s EPS estimate?
Kodiak Sciences Inc’s EPS estimate is -1.01.
How many shares outstanding does Kodiak Sciences Inc have?
Kodiak Sciences Inc has 61,048,428 shares outstanding.
What happened to Kodiak Sciences Inc’s price movement after its last earnings report?
Kodiak Sciences Inc reported an EPS of -$1.16 in its last earnings report, missing expectations of -$1.037. Following the earnings report the stock price went up 3.392%.
Which hedge fund is a major shareholder of Kodiak Sciences Inc?
Currently, no hedge funds are holding shares in KOD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kodiak Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.80 (42.09% Upside)
$31.80 (42.09% Upside)
Blogger Sentiment
Bullish
KOD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 557.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $60.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
287.86%
12-Months-Change
Fundamentals
Return on Equity
-207.92%
Trailing 12-Months
Asset Growth
-41.48%
Trailing 12-Months
Company Description
Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
KOD Stock 12 Month Forecast
Average Price Target
$31.80
▲(42.09% Upside)
Technical Analysis
Urogen Pharma
―
Nurix Therapeutics
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
Currently, No data available
---